Drugmakers' Commitment to Personalized Rx Growing Despite Barriers, PhRMA CEO Says
June 15, 2011
Drugmakers' Commitment to Personalized Rx Growing Despite Barriers, PhRMA CEO Says
John Castellani, CEO of the Pharmaceutical Research and Manufacturers of America, said that while the industry's commitment to using genomic strategies to advance targeted therapies is growing, the road ahead is fraught with scientific, regulatory, and reimbursement challenges.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- During Investor Day, Roche Highlights Personalized Medicine as Key Area for Future Growth
September 12, 2012 / Pharmacogenomics Reporter - Roche Receives FDA Nod for New PGx Indication for Tarceva in Metastatic NSCLC with Companion Dx
May 15, 2013 / Pharmacogenomics Reporter - PGx Drugs Xalkori, Zelboraf Show Strong Growth in First Quarter of 2013
May 1, 2013 / Pharmacogenomics Reporter - Pharmas and Dx Partners Race to Launch the First Personalized EGFR Inhibitor for Lung Cancer
January 16, 2013 / Pharmacogenomics Reporter - Diaceutics Report Sheds Doubt on Pharmas' Personalized Medicine Preparedness
June 15, 2011 / Pharmacogenomics Reporter